Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 7/20 | 0.40 |
| ▸ | JAK1 | P23458 | 4/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.37 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24033 | 0.91 | EGFR (0.51) | EGFRJAK2JAK1KDRPTK2 | |
| SCHEMBL23523 | 0.90 | LMNA (0.48) | EGFRJAK2JAK1LMNAMAPT | |
| SCHEMBL24403 | 0.88 | JAK2 (0.44) | JAK2FGFR1KDRMAPTPTK2 | |
| SCHEMBL24602 | 0.87 | RAD52 (0.46) | EGFRJAK2JAK1RAD52FGFR1 | |
| SCHEMBL24074 | 0.82 | JAK2 (0.48) | EGFRJAK2KDRPTK2JAK3 | |
| SCHEMBL24500 | 0.82 | JAK2 (0.38) | JAK2KDRLMNAPTK2JAK3 | |
| SCHEMBL23494 | 0.82 | SYK (0.44) | EGFRJAK2RAD52KDRPTK2 | |
| SCHEMBL23085 | 0.82 | EGFR (0.53) | EGFRJAK2JAK1MAPTPTK2 | |
| SCHEMBL23452 | 0.81 | SYK (0.45) | JAK2KDRPTK2FLT3SYK | |
| SCHEMBL23858 | 0.79 | POLB (0.45) | JAK2RAD52FGFR1MAPTPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | EGFR 1974/4885JAK2 5/4885JAK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.